Recent findings from Zoetis, in collaboration with the University of Pennsylvania New Bolton Center, have highlighted the comparative performance of leading equine orthobiologic devices (Pro-Stride APS, Restigen PRP, Alpha2EQ, and Arthrex ACP). The study underscores the importance of alpha-2-macroglobulin (A2M) and key cytokines in modulating inflammation and supporting joint health.

While these results provide valuable insights into the field, Intibio is proud to announce that its A2MG kit represents the next generation of A2M-based solutions. Unlike the devices evaluated in the Zoetis study, the Intibio A2MG kit is designed to directly isolate and concentrate A2M at relevant levels, ensuring a standardized, high-quality output with every preparation.

Key differentiators include:

• Targeted cell deprivated A2M enrichment – Purpose-built to deliver high and consistent concentrations of alpha-2-macroglobulin, the protein long recognized as critical in neutralizing cartilage-damaging enzymes while removing white blood cells and red blood cells from the blood plasma.
• Validated sterility protocols – Independent testing confirms the kit’s sterilization process eliminates bacterial contamination across all units tested, reinforcing clinician and patient safety.
• Simplicity and accessibility – A standardized protocol that can be easily adopted in equine practice, overcoming the variability reported in comparative PRP and APS systems.

As Zoetis’ findings highlight the variability of orthobiologic devices, Intibio’s A2MG kit stands apart by offering a dedicated, evidence-based, and validated solution for equine joint indications. This positions veterinarians to move beyond general platelet-based preparations toward a more precise, predictable, and targeted approach to regenerative solutions.

Together with Nupsala, Intibio remains committed to advancing standards in equine orthobiologics and empowering veterinarians with tools that deliver both clinical confidence and improved outcomes for horses.